Medataccess Completes Tens of Millions in Angel Round Funding

July 4, 2022, Medataccess recently announced the completion of an angel round of financing in the tens of millions of RMB. Led by Xiamen Kang Hong Wan and followed by Rui Xi Jing Cheng. The angel round of financing will be used for the construction of core technology services, team building and business expansion.

Founded in December 2021, Medataccess is a healthcare big data technology company based in China and serving the world, integrating medical services, statistics, real world study, evidence from health economics and market access strategy. We strive to be a one-stop full lifecycle data partner for healthcare Industry.

The educational background of the team includes biostatisticians with overseas background, Ph.D. in health economics and Ph.D. in medicine, etc. The core team has an average of more than 15 years of experience in the world's top 10 CROs and pharmaceutical companies. More than 300 clinical research experiences, covering multiple disease areas from Phase I to Phase IV, including tumor, cardiovascular, rheumatism and immunity, infectious diseases, etc. The Chinese team has rare international filing experience, including US FDA, European EMA, China NMPA, Japan PMDA, etc. Through real-world data research, we use artificial intelligence tools and digital clinical platforms to help companies build complete evidence of product value. Our team has a leading international perspective and extensive local practical experience in China in market access and product value assessment and innovative payments, providing practical solutions for market access in different scenarios.